Brise Pharmaceuticals
Stories
-
Brise Pharmaceuticals announces license agreement with AbbVie to advance migraine therapies
Brise said the agreement, entered in 2024, gives AbbVie global development and commercialization rights for two of Brise's preclinical migraine programs. The aggregated potential transaction value could reach up to US $757 million plus royalties on future sales.